All In Biotech

Drug Trial Radar · NCT07224581

Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder

A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 5, 2026

Primary completion

May 2027

Study completion Jul 2028

Sponsor

Lead sponsor
GRIN Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Aziende Chimiche Riunite Angelini Francesco S.p.A
First posted
Nov 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant. This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort). Participants in each cohort will be randomized 1:1 to receive active drug (radiprodil) or matching placebo (Part A). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil. The placebo-controlled portion is expected to be approximately 16 weeks for participants in Phase 3 Cohort 1 and 28 weeks for participants in Phase 3 Cohort 2. The study will evaluate the effect of radiprodil on seizures and non-seizure symptoms and assess safety.

Conditions

  • GRIN-related Neurodevelopmental Disorder

Interventions

  • RadiprodilDrug

    Radiprodil oral suspension

  • PlaceboDrug

    Placebo-to-match radiprodil oral suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Countable motor seizures (CMS)Time frame: 12 weeks
  2. Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)Time frame: 24 weeks
  3. Part B - Open-Label Extension: Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)Time frame: Average of 2 years

Locations

61 sites in 13 countries. Site status is shown where the registry gives one.

  • UCLA Health - Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • Lucile Packard Children's Hospital

    Palo Alto, California · Recruiting

  • Children's Hospital Colorado - Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Pediatric Neurology and Epilepsy

    Winter Park, Florida · Recruiting

  • Iowa Health Care - Pediatric Neurology & Specialty Clinic

    Iowa City, Iowa · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Northeast Regional Epilepsy Group (NEREG) - Hackensack

    Hackensack, New Jersey · Recruiting

  • Columbia University - Harkness

    New York, New York · Recruiting

  • Duke Health-Duke Children's Hospital & Health Center

    Durham, North Carolina · Recruiting

  • Duke University Health System

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Not yet recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Child Neurology Consultants of Austin - South Austin

    Austin, Texas · Recruiting

  • Children's Health Specialty Center, Dallas

    Dallas, Texas · Recruiting

  • The University of Texas Southwestern Medical Center (UTSW)

    Dallas, Texas · Recruiting

  • UTHealth Houston

    Houston, Texas · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • UZ Brussel

    Brussels, Belgium · Recruiting

  • University Hospital Antwerp

    Edegem, Belgium · Recruiting

  • Centre Hospitalier Universitaire d'Angers (CHU Angers)

    Angers, France · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • Hospices Civils de Lyon

    Bron, France · Recruiting

  • Hospices Civils De Lyon

    Bron, France · Recruiting

  • CHU de Dijon

    Dijon, France · Recruiting

  • AP HM Hopital d'enfants de la Timone

    Marseille, France · Recruiting

  • Hopital Necker Enfants Malades (APHP)

    Paris, France · Recruiting

  • Hôpital Necker Enfants Malades

    Paris, France · Recruiting

  • Hopital des Enfants ; CHU Toulouse

    Toulouse, France · Recruiting

  • CHU Toulouse - Hôpital Purpan

    Toulouse, France · Recruiting

  • Universitatsklinikum OWL der Universitat Bielefeld

    Bielefeld, Germany · Recruiting

  • Universitatsmedizin Greifswald Klinik und Poliklinik fur Frauenheilkunde und Geburtshilfe

    Greifswald, Germany · Recruiting

  • Klinik und Policlinik fur Kinder - und Jugendmedizin

    Leipzig, Germany · Recruiting

  • Universitatsklinikum Leipzig

    Leipzig, Saxony, Germany · Recruiting

  • IRCCS Fondazione Istituto Neurologico Nazionale Casimiro Mondino

    Pavia, Italy · Recruiting

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.